Teva and Barr settle patent dispute

Albany Molecular Research (AMRI) announced this morning an agreement with Teva Pharmaceuticals and Barr Laboratories to settle patent infringement litigation. The settlement involved the U.S. dispute over Allegra and Allegra D-12 between Teva, Barr and Sanofi-Aventis.

The settlement will result in an amended licensing agreement between AMRI and Sanofi-Aventis, which will allow Sanofi-Aventis to sublicense the patents to Teva and Barr. Sanofi-Aventis will pay ARMI $10 million in sublicensing fees.

Sanofi-Aventis will continue to pay royalties to AMRI for the products, as well as for authorized generics, for the remaining term of the patents, but sales of products outside of the United States will be unchanged. The royalties will be on all products containing fexofenadine hydrochloride, or combinations of fexofenadine hydrochloride and pseudoephedrine hydrochloride, generic ingredients in Allegra and Allegra D-12.

While the settlement protects patents only having to do with companies in the current litigation, there will be ongoing patent infringement litigation for other makers of generics in the U.S. and abroad.

- view the AMRI release
- check out the Teva release
- see what Barr had to say
- read the story in the Wall Street Journal
- see what BusinessWeek said

Suggested Articles

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?

Krystal Biotech has started on a new manufacturing facility for eventual commercial supply of gene therapies in its pipeline.

Chinese authorities have recommended trying AbbVie's HIV combo therapy Kaletra to treat the new coronavirus ravaging the country—and spreading fast.